Biocon Limited Overview
Pro stress-test →Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept.
Strategic Profile
Pro stress-test →It provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. The company was founded by Kiran Mazumdar-Shaw in 1978. The company operates across generics, biosimilars, and research segments with a global footprint.
Competitive Landscape
Pro stress-test →Biocon operates in the crowded Indian biopharmaceutical sector competing with other manufacturers and biosimilar developers. Key competitors include Lupin and other Indian pharmaceutical companies. The company differentiates through its biosimilars expertise and contract manufacturing capabilities serving global pharma clients.
Industry Context
Biocon Limited operates in Biopharmaceuticals & Generic Drugs Manufacturing.
Key facts
Founded: 1978 · Headquarters: Bengaluru, India · Employees: 16,561 · Revenue: $1.9B · Market cap: $6.6B